PL2802325T3 - Związki znieczulające i powiązane sposoby zastosowania - Google Patents
Związki znieczulające i powiązane sposoby zastosowaniaInfo
- Publication number
- PL2802325T3 PL2802325T3 PL13735638T PL13735638T PL2802325T3 PL 2802325 T3 PL2802325 T3 PL 2802325T3 PL 13735638 T PL13735638 T PL 13735638T PL 13735638 T PL13735638 T PL 13735638T PL 2802325 T3 PL2802325 T3 PL 2802325T3
- Authority
- PL
- Poland
- Prior art keywords
- related methods
- anesthetic compounds
- anesthetic
- compounds
- methods
- Prior art date
Links
- 230000003444 anaesthetic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586450P | 2012-01-13 | 2012-01-13 | |
| US201261622627P | 2012-04-11 | 2012-04-11 | |
| EP13735638.2A EP2802325B1 (en) | 2012-01-13 | 2013-01-11 | Anesthetic compounds and related methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2802325T3 true PL2802325T3 (pl) | 2017-11-30 |
Family
ID=48781947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13735638T PL2802325T3 (pl) | 2012-01-13 | 2013-01-11 | Związki znieczulające i powiązane sposoby zastosowania |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9156825B2 (enExample) |
| EP (2) | EP2802325B1 (enExample) |
| JP (1) | JP6196986B2 (enExample) |
| CN (2) | CN104168899B (enExample) |
| AU (1) | AU2013207811B2 (enExample) |
| BR (1) | BR112014017230A2 (enExample) |
| CA (1) | CA2861071C (enExample) |
| CY (1) | CY1118842T1 (enExample) |
| DK (1) | DK2802325T3 (enExample) |
| EA (1) | EA027976B1 (enExample) |
| ES (1) | ES2617536T3 (enExample) |
| HR (1) | HRP20170330T1 (enExample) |
| HU (1) | HUE030892T2 (enExample) |
| IN (1) | IN2014DN06132A (enExample) |
| LT (1) | LT2802325T (enExample) |
| NZ (1) | NZ627274A (enExample) |
| PL (1) | PL2802325T3 (enExample) |
| PT (1) | PT2802325T (enExample) |
| RS (1) | RS56025B1 (enExample) |
| SG (1) | SG11201403980VA (enExample) |
| SI (1) | SI2802325T1 (enExample) |
| SM (1) | SMT201700145T1 (enExample) |
| WO (1) | WO2013106717A1 (enExample) |
| ZA (1) | ZA201405248B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3360863B1 (en) * | 2015-10-10 | 2022-04-20 | Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd. | Etomidate derivative and intermediate, preparation method and use thereof |
| CN105663042A (zh) * | 2016-02-03 | 2016-06-15 | 北京蓝丹医药科技有限公司 | 一种稳定的麻醉药物脂肪乳及其制备方法 |
| CN107382870A (zh) * | 2016-05-17 | 2017-11-24 | 四川海思科制药有限公司 | N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途 |
| CN107445898A (zh) * | 2016-05-30 | 2017-12-08 | 四川海思科制药有限公司 | N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途 |
| CN107522662A (zh) * | 2016-06-16 | 2017-12-29 | 四川海思科制药有限公司 | N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途 |
| CN107641105A (zh) * | 2016-07-22 | 2018-01-30 | 四川海思科制药有限公司 | N‑取代咪唑羧酸酯类化合物及其制备方法和在医药上的用途 |
| CN106432163A (zh) * | 2016-09-29 | 2017-02-22 | 山东东方农药科技实业有限公司 | 一种螺环内酯类化合物、其合成方法以及其用途 |
| CN107652239B (zh) * | 2017-02-24 | 2020-08-04 | 四川大学华西医院 | N-取代咪唑羧酸酯类化合物、制备方法及用途 |
| CN109776512A (zh) * | 2018-01-30 | 2019-05-21 | 成都安诺晨创医药科技有限公司 | 一种n-取代咪唑甲酸酯类衍生物及其用途 |
| CN109053410A (zh) * | 2018-08-06 | 2018-12-21 | 兰博尔开封科技有限公司 | 一种合成1-羟基环己基甲酸的新工艺及应用 |
| UA130338C2 (uk) | 2018-09-26 | 2026-01-28 | Джянгсу Хенгруй Медісін Ко., Лтд. | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування |
| JP7408646B2 (ja) | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途 |
| CN109761906B (zh) * | 2019-03-02 | 2023-08-11 | 成都麻沸散医药科技有限公司 | 一种取代咪唑甲酸酯类衍生物及其用途 |
| CN110003188B (zh) * | 2019-03-27 | 2022-08-26 | 成都麻沸散医药科技有限公司 | 取代吡咯甲酸酯类衍生物及其用途 |
| CN112125915A (zh) | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| CN110669017B (zh) * | 2019-10-11 | 2023-08-04 | 成都麻沸散医药科技有限公司 | 多取代三唑甲酸酯类衍生物及其用途 |
| CN112174890B (zh) * | 2020-10-09 | 2022-05-27 | 成都麻沸散医药科技有限公司 | 酮取代杂环化合物及其麻醉作用 |
| US12570612B2 (en) | 2019-10-11 | 2026-03-10 | Chengdu Mfs Pharma. Co., Ltd. | Substituted nitrogen heterocyclic compound and anesthetic effect thereof |
| AU2020402006A1 (en) | 2019-12-12 | 2022-07-07 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof |
| BR112022011632A2 (pt) | 2019-12-16 | 2022-10-04 | Jiangsu Hengrui Medicine Co | Conjugado análogo de anticorpo exatecano anti-cea e uso farmacêutico do mesmo |
| JP7821733B2 (ja) | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| US20230101735A1 (en) | 2020-01-22 | 2023-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof |
| CN115103691B (zh) | 2020-03-25 | 2025-01-24 | 苏州盛迪亚生物医药有限公司 | 一种含抗体药物偶联物的药物组合物及其用途 |
| CA3175048A1 (en) | 2020-03-25 | 2021-09-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for antibody medicament conjugate |
| MX2022011808A (es) | 2020-03-25 | 2022-12-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Conjugado de anticuerpo anti-psma-analogo de exatecan y uso medico del mismo. |
| MX2024000893A (es) | 2021-07-22 | 2024-02-06 | Shanghai Senhui Medicine Co Ltd | Farmaco conjugado de un derivado de eribulina. |
| TW202346346A (zh) | 2021-12-23 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途 |
| KR20260040624A (ko) | 2023-07-25 | 2026-03-25 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | c-Met를 표적으로 하는 항체-약물 접합체 및 이의 의학적 용도 |
| EP4778941A1 (en) | 2023-09-15 | 2026-07-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Her3/met binding molecule and pharmaceutical use thereof |
| WO2025195256A1 (zh) * | 2024-03-22 | 2025-09-25 | 四川科伦药物研究院有限公司 | 羧酸酯类化合物及其制备方法和用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3354173A (en) | 1964-04-16 | 1967-11-21 | Janssen Pharmaceutica Nv | Imidazole carboxylates |
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CA1066709A (en) | 1975-03-10 | 1979-11-20 | Walter A.M. Helsen | Preparation of loweralkyl imidazole carboxylates |
| US4038286A (en) | 1975-03-10 | 1977-07-26 | Janssen Pharmaceutica N.V. | Racemates and optical isomers of 1-(1-phenylethyl)-1h-imidazole-5-carboylic acid derivatives |
| GR64915B (en) | 1978-09-14 | 1980-06-09 | Janssen Pharmaceutica Nv | Improved etomidate-containing compositions |
| EP0277384A3 (en) | 1986-12-24 | 1990-05-23 | Janssen Pharmaceutica N.V. | 1h-imidazole-5-carboxylic acid derivatives |
| US4878940A (en) | 1987-04-02 | 1989-11-07 | Janssen Pharmaceutica N.V. | Herbicidal 1,5-substituted 1H-imidazoles |
| US5041554A (en) | 1989-01-31 | 1991-08-20 | Merrell Dow Pharmaceuticals Inc. | Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions |
| CA2008616C (en) | 1989-01-31 | 2000-07-18 | Roger A. Parker | Aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions |
| US5019583A (en) | 1989-02-15 | 1991-05-28 | Glaxo Inc. | N-phenyl-N-(4-piperidinyl)amides useful as analgesics |
| US5242939A (en) * | 1990-09-28 | 1993-09-07 | Warner-Lambert Company | Anilide derivatives with angiotensin ii antagonist properties |
| JP3374922B2 (ja) | 1991-05-09 | 2003-02-10 | 日産化学工業株式会社 | 複素環式第３級アミンの製造方法 |
| JPH06345728A (ja) | 1993-06-11 | 1994-12-20 | Nissan Chem Ind Ltd | Ｎ−置換アゾール誘導体の製造方法 |
| US5466700A (en) | 1993-08-30 | 1995-11-14 | Glaxo Wellcome Inc. | Anesthetic use of N-phenyl-N-(4-piperidinyl)amides |
| US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
| EP1383445A4 (en) | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
| JP2005514412A (ja) | 2001-12-27 | 2005-05-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 中枢神経系疾患を処置するために有用なアロイルピロールヘテロアリールおよびメタノール類 |
| US7189859B2 (en) | 2003-08-06 | 2007-03-13 | Ilse Zolle | Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives |
| US20080206138A1 (en) | 2003-08-06 | 2008-08-28 | Ilse Zolle | Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives |
| CA2576971A1 (en) | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| US7592362B2 (en) * | 2006-01-19 | 2009-09-22 | Pfizer Limited | Substituted imidazoles |
| AU2007208819B2 (en) | 2006-01-24 | 2012-06-07 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel histidine derivative |
| EP2035393A2 (en) * | 2006-06-09 | 2009-03-18 | GE Healthcare Limited | Synthesis and evaluation of 18f-labelled alkyl-1-[(r)-1-phenylethyl]-1h-imidazole-5-carboxylate as a tracer for the quantification of beta-11-hydroxylase enzyme in the adrenal glands |
| CN101743227B (zh) | 2007-07-23 | 2013-09-25 | 日本脏器制药株式会社 | 组氨酸衍生物 |
| RU2540116C2 (ru) | 2008-03-31 | 2015-02-10 | Дзе Дженерал Хоспитал Корпорейшн | Аналоги этомидата с улучшенными фармакокинетическими и фармакодинамическими свойствами |
| WO2011005969A2 (en) * | 2009-07-10 | 2011-01-13 | The General Hospital Corporation | Etomidate analogues that do not inhibit adrenocortical steroid synthesis |
-
2013
- 2013-01-11 CN CN201380014062.1A patent/CN104168899B/zh active Active
- 2013-01-11 RS RS20170208A patent/RS56025B1/sr unknown
- 2013-01-11 EP EP13735638.2A patent/EP2802325B1/en active Active
- 2013-01-11 LT LTEP13735638.2T patent/LT2802325T/lt unknown
- 2013-01-11 CN CN201710140475.4A patent/CN107382812A/zh active Pending
- 2013-01-11 BR BR112014017230-7A patent/BR112014017230A2/pt not_active IP Right Cessation
- 2013-01-11 NZ NZ627274A patent/NZ627274A/en not_active IP Right Cessation
- 2013-01-11 DK DK13735638.2T patent/DK2802325T3/en active
- 2013-01-11 ES ES13735638.2T patent/ES2617536T3/es active Active
- 2013-01-11 HR HRP20170330TT patent/HRP20170330T1/hr unknown
- 2013-01-11 US US14/371,651 patent/US9156825B2/en active Active
- 2013-01-11 EP EP16198942.1A patent/EP3184512B1/en active Active
- 2013-01-11 CA CA2861071A patent/CA2861071C/en active Active
- 2013-01-11 AU AU2013207811A patent/AU2013207811B2/en active Active
- 2013-01-11 WO PCT/US2013/021245 patent/WO2013106717A1/en not_active Ceased
- 2013-01-11 PL PL13735638T patent/PL2802325T3/pl unknown
- 2013-01-11 JP JP2014552332A patent/JP6196986B2/ja active Active
- 2013-01-11 EA EA201491362A patent/EA027976B1/ru not_active IP Right Cessation
- 2013-01-11 IN IN6132DEN2014 patent/IN2014DN06132A/en unknown
- 2013-01-11 PT PT137356382T patent/PT2802325T/pt unknown
- 2013-01-11 SM SM20170145T patent/SMT201700145T1/it unknown
- 2013-01-11 SG SG11201403980VA patent/SG11201403980VA/en unknown
- 2013-01-11 SI SI201330552A patent/SI2802325T1/sl unknown
- 2013-01-11 HU HUE13735638A patent/HUE030892T2/hu unknown
-
2014
- 2014-07-17 ZA ZA2014/05248A patent/ZA201405248B/en unknown
-
2015
- 2015-07-24 US US14/808,413 patent/US9522136B2/en active Active
-
2016
- 2016-11-10 US US15/348,790 patent/US9820971B2/en active Active
-
2017
- 2017-02-24 CY CY20171100255T patent/CY1118842T1/el unknown
- 2017-10-19 US US15/788,351 patent/US10154991B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201405248B (en) | Anesthetic compounds and related methods of use | |
| IL276761A (en) | Methods of inducing coma | |
| SG11201504049VA (en) | Compounds and their methods of use | |
| ZA201502503B (en) | Hppd variants and methods of use | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| SG11201502343RA (en) | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| ZA201308859B (en) | Quinazolines as therapeutic compounds and related methods of use | |
| HUE043894T2 (hu) | Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei | |
| ZA201303793B (en) | Substituted quinoline compounds and methods of use | |
| IL222227A0 (en) | Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use | |
| EP2709999A4 (en) | CHINAZOLIN-7-ETHER COMPOUNDS AND ITS APPLICATION | |
| ZA201406082B (en) | Use of ccr3-inhibitors | |
| ZA201408856B (en) | Heteroaryl compounds and methods of use thereof | |
| ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
| GB201216381D0 (en) | New compounds and medical uses | |
| GB201208970D0 (en) | New compounds and medical uses | |
| AU2012900650A0 (en) | Compounds and methods of their use | |
| AU2012900651A0 (en) | Compounds and methods of their use | |
| GB201104872D0 (en) | New compounds and medical uses | |
| GB201104875D0 (en) | New compounds and medical uses |